Blog Posts

Is Less Treatment Needed After Surgery for Early-Stage HER2+ Breast Cancer – Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology/X

Aug 6, 2025, 08:08

Is Less Treatment Needed After Surgery for Early-Stage HER2+ Breast Cancer – Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology shared a post on X:

“New Trial!

Ada Waks of Dana-Farber Cancer Institute leads Alliance for Clinical Trials in Oncology A012303 (ShortStop-HER2), a study exploring if less treatment is needed after surgery for people with early-stage HER2+ breast cancer who had no cancer left after chemo + HER2 therapy (before surgery).”

Sarah Sammons, Associate Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute, shared Alliance for Clinical Trials in Oncology‘s post, adding:

“This is where the importance of government cancer funding comes in.

My brilliant colleague designing a large trial to give less trastuzumab to HER2+ patients who achieve pCR.”

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Blog Posts

OncoDaily

Blog Posts

Is Less Treatment Needed After Surgery for Early-Stage HER2+ Breast Cancer – Alliance for Clinical Trials in Oncology